Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Cardenal

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Lung Cancer (Amsterdam, Netherlands)|February 13, 2003
Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II studyF Cardenal, M Domine, B Massutí, et al.
Revista Clinica Espanola|November 1, 1994
[A randomized study of navelbine compared to navelbine and cisplatin compared to vindesine and cisplatin in the treatment of inoperable non-small-cell lung carcinoma. The results of a European multicenter study including 612 patients]J L González Larriba, V Alberola, P Lianes, et al.
American Journal of Clinical Oncology|August 24, 2000
Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized studyU Gatzemeier, J P Kleisbauer, P Drings, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 11, 2010
A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with cisplatin-docetaxel, in patients with unresectable locally advanced non-small-cell lung cancerS Senan, F Cardenal, J Vansteenkiste, et al.
Oncology|January 1, 1988
Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancerM C Alonso-Muñoz, M B Ojeda-González, M Beltran-Fabregat, et al.
Cancer Chemotherapy and Pharmacology|October 12, 2012
Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancerM Provencio, C Camps, M Cobo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1997
Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survivalF Graus, J Dalmou, R Reñé, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancerF Cardenal, M P López-Cabrerizo, A Antón, et al.
Clinical Lung Cancer|January 22, 2004
Preoperative high-dose cisplatin versus moderate-dose cisplatin combined with ifosfamide and mitomycin in stage IIIA (N2) non small-cell lung cancer: results of a randomized multicenter trialE Felip, R Rosell, V Alberola, et al.
Lung Cancer (Amsterdam, Netherlands)|July 15, 2010
Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbineN Viñolas, M Provencio, N Reguart, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Lung Cancer (Amsterdam, Netherlands)|February 13, 2003
Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II studyF Cardenal, M Domine, B Massutí, et al.
Revista Clinica Espanola|November 1, 1994
[A randomized study of navelbine compared to navelbine and cisplatin compared to vindesine and cisplatin in the treatment of inoperable non-small-cell lung carcinoma. The results of a European multicenter study including 612 patients]J L González Larriba, V Alberola, P Lianes, et al.
American Journal of Clinical Oncology|August 24, 2000
Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized studyU Gatzemeier, J P Kleisbauer, P Drings, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 11, 2010
A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with cisplatin-docetaxel, in patients with unresectable locally advanced non-small-cell lung cancerS Senan, F Cardenal, J Vansteenkiste, et al.
Oncology|January 1, 1988
Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancerM C Alonso-Muñoz, M B Ojeda-González, M Beltran-Fabregat, et al.
Cancer Chemotherapy and Pharmacology|October 12, 2012
Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancerM Provencio, C Camps, M Cobo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1997
Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survivalF Graus, J Dalmou, R Reñé, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancerF Cardenal, M P López-Cabrerizo, A Antón, et al.
Clinical Lung Cancer|January 22, 2004
Preoperative high-dose cisplatin versus moderate-dose cisplatin combined with ifosfamide and mitomycin in stage IIIA (N2) non small-cell lung cancer: results of a randomized multicenter trialE Felip, R Rosell, V Alberola, et al.
Lung Cancer (Amsterdam, Netherlands)|July 15, 2010
Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbineN Viñolas, M Provencio, N Reguart, et al.
Pageof 4